Pharmacokinetic and pharmacodynamic assays
Serial blood samples for PK and pharmacodynamic analyses were collected for each dosing schedule after the first and last doses in cycle 1. Additional blood samples for assessment of the food effect on trotabresib PK in part C were collected during cycle 2. The food effect–evaluable population comprised all patients with adequate PK data to allow calculation of trotabresib AUC from time 0 (day 1) to day 22 from both the fed and fasted treatment periods and who had completed a 4-h post-dose fast during the fasted cycle or consumed the entire high-fat, high-calorie meal during the fed cycle and had received all trotabresib doses during both treatment periods.Changes in peripheral 